BioLargo, Inc.
BLGO
$0.20
-$0.0025-1.24%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -31.32% | -16.32% | 62.84% | 246.75% | 27.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -31.32% | -16.32% | 62.84% | 246.75% | 27.20% |
| Cost of Revenue | -29.16% | -16.43% | 112.53% | 358.85% | 30.12% |
| Gross Profit | -33.75% | -16.19% | 20.00% | 160.93% | 24.09% |
| SG&A Expenses | 15.01% | 14.05% | -8.12% | 34.23% | 29.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.10% | 5.86% | 29.85% | 92.94% | 30.91% |
| Operating Income | -144.04% | -164.48% | 29.08% | 44.86% | -59.96% |
| Income Before Tax | -147.87% | -69.80% | 29.71% | 52.03% | -56.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -147.87% | -69.80% | 29.71% | 52.03% | -56.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 109.86% | 146.74% | 69.81% | 13.76% | 47.77% |
| Net Income | -181.71% | -39.09% | 55.25% | 66.79% | -65.99% |
| EBIT | -144.04% | -164.48% | 29.08% | 44.86% | -59.96% |
| EBITDA | -141.82% | -161.79% | 29.79% | 46.22% | -63.96% |
| EPS Basic | -171.43% | -36.00% | 57.14% | 68.09% | -55.56% |
| Normalized Basic EPS | -250.00% | -300.00% | 77.27% | 72.00% | -100.00% |
| EPS Diluted | -171.43% | -36.00% | 57.14% | 68.09% | -55.56% |
| Normalized Diluted EPS | -250.00% | -300.00% | 77.27% | 72.00% | -100.00% |
| Average Basic Shares Outstanding | 2.37% | 3.81% | 4.36% | 4.03% | 4.84% |
| Average Diluted Shares Outstanding | 2.37% | 3.81% | 4.36% | 4.03% | 4.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |